VERICIGUAT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H16F2N8O2
Molecular Weight	426.3795
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=CC=CC=C3F)C4=NC=C(F)C=C24

InChI

InChIKey=QZFHIXARHDBPBY-UHFFFAOYSA-N

InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)

HIDE SMILES / InChI

Molecular Formula	C19H16F2N8O2
Molecular Weight	426.3795
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Vericiguat, discovered at Bayer, is the first soluble guanylate cyclase (sGC) stimulator. Vericiguat is currently being studied in a Phase III clinical program for the treatment of heart failure with reduced ejection fraction (HFrEF).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Soluble guanylate cyclase 34	Activator 1,430		1005.0 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heart Failure 7	Primary		Phase III 656	Unknown

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.

Route of Administration: Oral

In Vitro Use Guide

Studies on the in vitro effects of Vericiguat on highly purified sGC (soluble guanylate cyclase) revealed that Vericiguat (0.01 uM to 100 uM) stimulates recombinant sGC concentration dependently, by 1.7-fold to 57.6-fold.

Substance Class	Chemical
Record UNII	LV66ADM269
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

VERICIGUAT

Official Name

English

METHYL N-(4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)PYRIMIDIN-5-YL)CARBAMATE

Systematic Name

English

vericiguat [INN]

Common Name

English

METHYL (4,6-DIAMINO-2-(5-FLUORO-1-((2-FLUOROPHENYL)METHYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL(PYRIMIDIN-5-YL)CARBAMATE

Systematic Name

English

METHYL (4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)PYRIMIDIN-5-YL)CARBAMATE

Systematic Name

English

Showing 1 to 5 of 12 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Agent Affecting Cardiovascular System

NCI_THESAURUS

C29707

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

FDA UNII

LV66ADM269

PRIMARY

WIKIPEDIA

Vericiguat

PRIMARY

CHEBI

142432

PRIMARY

INN

9805

PRIMARY

DRUG BANK

DB15456

PRIMARY

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					5G76IGF54K

VERICIGUAT HYDROCHLORIDE

SALT/SOLVATE -> PARENT


					76UB6O122H

ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2

TRANSPORTER -> SUBSTRATE

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

Protein binding (primarily to serum albumin) of vericiguat is about 98%.

Interaction Type:

BINDING

Amount:

98 % (average)


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE

Amount:


					0RFO7VC96N

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1

METABOLIC ENZYME -> SUBSTRATE

Amount:

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					LV66ADM269

VERICIGUAT

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

Name	Property Type	Amount	Referenced Substance	Parameters
Volume of Distribution	PHARMACOKINETIC	44 LITERS (average)	`LV66ADM269` VERICIGUAT	IN HEALTHY SUBJECTS PHARMACOKINETIC

Tmax	PHARMACOKINETIC	1 hours (average)	`LV66ADM269` VERICIGUAT	FASTED STATE PHARMACOKINETIC

ABSOLUTE BIOAVAILABILITY	PHARMACOKINETIC	93 % (average)	`LV66ADM269` VERICIGUAT	FED CONDITION PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC	30 hours (average)	`LV66ADM269` VERICIGUAT	IN PATIENTS WITH HEART FAILURE NUCLEIC ACID FEATURE

Tmax	PHARMACOKINETIC	4 hours (average)	`LV66ADM269` VERICIGUAT	HIGH-FAT, HIGH-CALORIE MEAL PHARMACOKINETIC